Neuroblastoma screening in infants: Introduction
β Scribed by Philip, Thierry
- Publisher
- John Wiley and Sons
- Year
- 1998
- Tongue
- English
- Weight
- 21 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
β¦ Synopsis
A pre-consensus conference on the question of screening infants for neuroblastoma was held in Lyon, December 7-8, 1997. It was convened by the Association pour le De Β΄pistage du Neuroblastome and with the support of the Centre d'Γtudes, d'Γchanges et de Recherche Rho Λne-Alpes-Canada-Quebec of the Centre Jacques Cartier, Lyon. The logo of the Centre heads these introductory remarks.
The title of the conference was, ''Should infants be screened for neuroblastoma?'' The issue was examined in depth, with review of the biology of neuroblastoma, the statistical methods appropriate to screening, the clinicians' expectations of such screening efforts, the ethical and psychological aspects of the screening issue, and the latest appropriate technical methods. A review of the first 30 years of screening, pioneered by the first investigators in Japan, provided an overview of what has been accomplished and learned to date.
The detailed manuscripts dealing with these important matters have been collected in this issue of Medical and Pediatric Oncology.
π SIMILAR VOLUMES
Results of a 11-year-experience with mass screening for neuroblastoma in 6-month-old infants in Japan are presented. From 11,284,837 infants who were screened, 1,400 cases of neuroblastoma were detected, an incidence of 1/ 6,500-7,500 infants by HPLC screening. Most of the cases (75%) were at stages
The mass screening (MS) of neuroblastoma has been undertaken in Japan by measuring urinary catecholamine metabolites in infants at the age of 6 months. To clarify the biological characteristics of MS-positive (MS Ψ ) tumors in infants and MS-negative (MS Ψ )/late-presenting tumors in young children,
Three infants with congenital neuroblastoma received a primary series of diptheria-pertassis-tetanus (DPT) immunizations during and after courses of chemotherapy with immunosuppressive medications. Serum IgG, IgA and IgM levels and antidiphtheria and antitetanus antibody responses were measured and